Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA)

UCB

Status: Completed

Conditions: Epilepsy

Study type: Observational

Funder types: Industry

Identifiers

NCT00302991

N01247

EPIKA

Details and patient eligibility

About

Observational, multicentre, epidemiological study to determine the HRQOL of patients with epilepsy according to treatment sub-group and to validate the Spanish version of the Adverse Events Profile, produced by G. Baker et al. Three treatment groups will be examined: patients receiving only a new anti-epilepsy drug (AED), patients receiving a "classic" AED; patients receiving combination therapy.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Epileptic adult patients treated at a stable dose with one or more AEDs for ≥ 3 months

Exclusion criteria

• Symptomatic epilepsy due to malignant brain tumour or progressive brain disease.
• Confirmed diagnosis of a concomitant chronic disease